Everything below concerns AOD9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
=== Oxytalan fibers === Oxytalan fibers are unique to the PDL and are elastic in nature. It inserts into cementum and runs in two directions: parallel to root surface and oblique to root surface. The function is thought to maintain the patency of blood vessels during occlusal loading. Further research is needed to determine the function of oxytalan fibers.
Bodybuilders were previously thought to require protein with a higher BV than that of soy, which was additionally avoided due to its alleged estrogenic (female hormone) properties, though more recent studies have shown that soy actually contains phytoestrogens which compete with estrogens in the male body and can block estrogenic actions. Soy, flax, and other plant-based foods that contain phytoestrogens are also beneficial because they can inhibit some pituitary functions while stimulating the liver's P450 system (which eliminates hormones, drugs, and waste from the body) to more actively process and excrete excess estrogen.
=== Brand names === Free alcohol gonadorelin has been sold under the brand names Cryptocur, Cystoréline, Fertagyl, GnRH Serono, Gonadorelin, HRF, Kryptocur, LH-RH, Luforan, Pulstim, Relefact, Relisorm L, Stimu-LH, and Wyeth-Ayest HRF. Gonadorelin diacetate has been sold under the brand names Kryptocur, LHRH Ferring, Lutamin, Lutrelef, Lutrepulse, Relisorm L, and Relisorm. GnRH hydrochloride has been sold under the brand names Factrel, HRF, and Luforan. Additional brand names of gonadorelin and its salts include Acegon, Conceptyl, Cystorelin, Enagon, Equity Oestrus Control, Fertagyl Cattle, Fertiral, Gonabreed, Gonadorelin Interpharm, Gonasyn, Gonavet, Hypocrine, Improvest, LH RH Tanabe, LHRH Ferring, LH-RH Ferring, LH-RH Tanabe, Oestracton, OvaCyst, Ovsynch, OVsynch, Ovurelin, Ovarelin, and Relefact LH-RH. The majority of these brand names are for veterinary use.
=== Physical therapy === During the immobilization period, it is important to keep the foot flexible by lightly stretching the foot and calf regularly. As the plantar fascia recovers, physical therapy exercises help stabilize the ankle and correct gait patterns that may have contributed to the tear. Stretching and strengthening exercises decrease the chance of reinjury.
where the λi are the Lagrange multipliers, one for each element. This allows each of the Nj and λj to be treated independently, and it can be shown using the tools of multivariate calculus that the equilibrium condition is given by
Sources: en.wikipedia.org
=== Sources === Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, eds. (2003). Fitzpatrick's Dermatology in General Medicine (6th ed.). McGraw-Hill. ISBN 978-0-07-138076-8. James W, Berger T, Elston D (2005). Andrews' Diseases of the Skin: Clinical Dermatology (10th ed.). Saunders. ISBN 978-0-7216-2921-6. Rapini RP, Bolognia JL, Jorizzo JL (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 978-1-4160-2999-1.
=== Refresh frequency limits for standard video === Color depth of 8 bpc (24 bit/px or 16.7 million colors) is assumed for all formats in these tables. This is the standard color depth used on most computer displays. Note that some operating systems refer to this as "32-bit" color depth—this is the same as 24-bit color depth. The 8 extra bits are for alpha channel information, which is only present in software. At the transmission stage, this information has already been incorporated into the primary color channels, so the actual video data transmitted across the cable only contains 24 bits per pixel.
=== Next generation PEGylation === Chilkoti's research group has developed next-generation polyethylene glycol (PEG)-like conjugates that overcome the immunogenicity issues associated with traditional PEGylation. PEGylation—the attachment of polyethylene glycol (PEG) to biologics—is commonly used to increase their half-life or reduce their immunogenicity, but PEG has itself proven to be antigenic and can elicit a serious anaphylactic response. To overcome these limitations, he designed a new PEG-like stealth hyperbranched polymer that breaks up the long antigenic ethylene glycol sequence in PEG and presents them as much shorter side-chains along a polymer backbone. Peptides and proteins conjugated to this next-generation PEG-like polymer show even longer circulation than PEG conjugates, do not bind to pre-existing anti-PEG antibodies that most people have developed, and do not generate an immune response to this new polymer. He has demonstrated the utility of this technology with a peptide drug for type 2 diabetes, an enzyme drug used to treat gout and an aptamer drug.
A central campaign theme for Trump's second presidential bid was "retribution". Trump framed the 2024 election as "the final battle", and openly promised to leverage the power of the presidency for political reprisals. Trump heavily ran on immigration as a central campaign focus. Trump's campaign focused on dark and apocalyptic rhetoric about the state of the country and predicting doom if he did not win. The Associated Press stated that "Trump's rallies take on the symbols, rhetoric and agenda of Christian nationalism." During his 2024 presidential campaign, Trump made numerous false and misleading statements. Trump has been described as using the "big lie" and firehose of falsehood propaganda techniques.
Sources: en.wikipedia.org
Wiederrecht GJ, Brown GM (1984). "Purification and properties of the enzymes from Drosophila melanogaster that catalyze the conversion of dihydroneopterin triphosphate to the pyrimidodiazepine precursor of the drosopterins". J. Biol. Chem. 259 (22): 14121–7. doi:10.1016/S0021-9258(18)89865-9. PMID 6438092.
The first use of small-molecule drugs to treat cancer was in the early 20th century, although the specific chemicals first used were not originally intended for that purpose. Mustard gas was used as a chemical warfare agent during World War I and was discovered to be a potent suppressor of hematopoiesis (blood production). A similar family of compounds known as nitrogen mustards were studied further during World War II at the Yale School of Medicine. It was reasoned that an agent that damaged the rapidly growing white blood cells might have a similar effect on cancer. Therefore, in December 1942, several people with advanced lymphomas (cancers of the lymphatic system and lymph nodes) were given the drug by vein, rather than by breathing the irritating gas. Their improvement, although temporary, was remarkable. Concurrently, during a military operation in World War II, following a German air raid on the Italian harbour of Bari, several hundred people were accidentally exposed to mustard gas, which had been transported there by the Allied forces to prepare for possible retaliation in the event of German use of chemical warfare. The survivors were later found to have very low white blood cell counts. After WWII was over and the reports declassified, the experiences converged and led researchers to look for other substances that might have similar effects against cancer. The first chemotherapy drug to be developed from this line of research was mustine.
== N == NAA – Neutron activation analysis ND – Neutron diffraction NDP – Neutron depth profiling NEXAFS – Near edge X-ray absorption fine structure NIS – Nuclear inelastic scattering/absorption NMR – Nuclear magnetic resonance spectroscopy NOESY – Nuclear Overhauser effect spectroscopy NRA – Nuclear reaction analysis NSOM – Near-field optical microscopy
Nadolol is a non-selective beta blocker; that is, it non-selectively blocks both beta-1 and beta-2 receptors. It has a preference for beta-1 receptors, which are predominantly located in the heart, thereby inhibiting the effects of catecholamines and causing a decrease in heart rate and blood pressure. Its inhibition of beta-2 receptors, which are mainly located in the bronchial smooth muscle of the airways, leads to airway constriction similar to that seen in asthma. Inhibition of beta-1 receptors in the juxtaglomerular apparatus of the kidney inhibits the renin–angiotensin system, causing a decrease in vasoconstriction and a decrease in water retention. Nadolol's inhibition of beta-1 receptors in the heart and kidney leads to its effects on lowering blood pressure. The drug impairs AV node conduction and decreases sinus rate. Nadolol may also increase plasma triglycerides and decrease HDL-cholesterol levels.
22 December A network model analysis suggests that temporary overshoots of climate change – increasing global temperature beyond Paris Agreement goals temporarily as often projected – can increase risks of climate tipping cascades "by up to 72%". In a paywalled article, scientists provide 3D imaging and model analysis to reveal main causes, mechanics, and potential mitigations of the problematic prevalent lithium-ion battery degradation over charge cycles. 26 December – Bio- and electrical engineers prove for the first time that human cerebral organoids transplanted into mice (see 17 Aug 21 and 12 Oct) functionally integrate with their visual cortex. 27 December – Scientists report that a species of Halteria, a single-celled protozoan, is the first known organism for which "a virus-only diet ... is enough to fuel the physiological growth and even population growth".
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.